Drug Trial Radar · NCT07123155
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Oct 30, 2025
Primary completion
Aug 8, 2027
Study completion Aug 8, 2027
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- Aug 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and exploratory clinical efficacy of S-606001 in adult participants with LOPD as an add-on to ERT.
Conditions
- Pompe Disease
Interventions
S-606001Drug
S-606001 administered orally
PlaceboDrug
S-606001 matching placebo administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Percent Forced Vital Capacity (%FVC) at Week 52Time frame: Baseline, Week 52
Locations
28 sites in 9 countries. Site status is shown where the registry gives one.
University of California - Irvine Medical Center
Irvine, California · Recruiting
University of Florida (UF) - Gainesville
Gainesville, Florida · Recruiting
Emory University Hospital
Atlanta, Georgia · Recruiting
Washington University in St. Louis
St Louis, Missouri · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania · Recruiting
Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)
Fairfax, Virginia · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Aarhus University Hospital
Aarhus, Denmark · Recruiting
HLC Hopital Pierre Wertheimer
Bron, France · Recruiting
AP-HP Hopital Raymond Poincare
Garches, France · Recruiting
Centre de Reference des Maladies Neuromusculaires et de la SLA - AP-HM Hopital de La Timone
Marseille, France · Recruiting
CHU de Nice - Hopital Pasteur 2 - Centre de reference des Maladies Neuromusculaires
Nice, France · Not yet recruiting
Universitaetsklinikum Halle (Saale)
Halle, Germany · Recruiting
SphinCS GmbH
Höchheim, Germany · Recruiting
Klinikum der Ludwig-Maximilians-Universitaet Muenchen
München, Germany · Recruiting
A.O.U. Policlinico "G. Martino"
Messina, Italy · Recruiting
AOU Citta della Salute e della Scienza di Torino - Ospedale le Molinette
Torino, Italy · Recruiting
Erasmus MC
GE Rotterdam, GE Rotterdam, Netherlands · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Universitari i Politecnic La Fe
Valencia, Spain · Recruiting
Queen Elizabeth Hospital Birmingham
Birmingham, United Kingdom · Recruiting
National Hospital for Neurology & Neurosurgery
London, United Kingdom · Recruiting
Royal Free London NHS Foundation Trust
London, United Kingdom · Recruiting
Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom · Recruiting
Salford Royal Hospital
Salford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.